Nebiscon (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebiscon, is a beta blocker presented as an oral dosage form for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nebiscon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist indicated for cardiovascular conditions. Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. Heart failure: improves left‑ventricular function and decreases hospitalization rates.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness during initial therapy. - Nasal congestion or rhinorrhea. - Bradycardia: heart rate below 60 bpm. - Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension with syncope. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatic enzyme elevation indicating liver stress. - Bronchospasm in patients with reactive airway disease. - Cardiogenic shock in severe heart failure.

Before initiating Nebivolol, consider patient‑specific factors and monitor for adverse events. - Renal impairment: use with caution and monitor renal function. - Hepatic impairment: dose adjustment may be required. - Concomitant beta‑blockers: risk of excessive bradycardia. - Pregnancy: safety not established; avoid unless clearly needed. - Elderly patients: monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nebivolol can interact with several drug classes; awareness helps prevent clinically relevant events.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block. - Clonidine: abrupt discontinuation may cause rebound hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive hypotensive effect. - Diuretics: potential electrolyte disturbances. - SSRIs or other antidepressants: possible pharmacodynamic interaction affecting blood pressure.